김영민 (POSTECH)

한빛사논문

조회275

POSTECH

CV File 130 kb

Cell Rep. Med., 2024 Jan 16;5(1):101362 | https://doi.org/10.1016/j.xcrm.2023.101362 Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells

Dong-il Kwon,^1,5 Subin Park,^1,5 Yujin L. Jeong,^1,5 Young-Min Kim,^1,5 Jeongyong Min,¹ Changhyung Lee,¹ Jung-ah Choi,³

Yoon Ha Choi,¹ Hyun-Jung Kong,⁴ Youngwon Choi,⁴Seungtae Baek,² Kun-Joo Lee,¹ Yeon-Woo Kang,¹ Chaerim Jeong,¹

Gihoon You,¹ Youngsik Oh,¹ Sun-Kyoung Im,² Manki Song,³ Jong Kyoung Kim,¹ Jun Chang,⁴ Donghoon Choi,^2,*and Seung-Woo Lee ^1,6,*

¹Department of Life Sciences, Pohang University of Science and Technology, Pohang 37666, Republic of Korea

²Research Institute of NeoImmuneTech Co., Ltd., Pohang 37666, Republic of Korea

³Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea

⁴Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea

⁵These authors contributed equally

⁶Lead contact

^*Corresponding authors: correspondence to Donghoon Choi or Seung-Woo Lee

Abstract

Repeated pandemics caused by the influenza virus and severe acute respiratory syndrome coronavirus (SARS-CoV) have resulted in serious problems in global public health, emphasizing the need for broad-spectrum antiviral therapeutics against respiratory virus infections. Here, we show the protective effects of long-acting recombinant human interleukin-7 fused with hybrid Fc (rhIL-7-hyFc) against major respiratory viruses, including influenza virus, SARS-CoV-2, and respiratory syncytial virus. Administration of rhIL-7-hyFc in a therapeutic or prophylactic regimen induces substantial antiviral effects. During an influenza A virus (IAV) infection, rhIL-7-hyFc treatment increases pulmonary T cells composed of blood-derived interferon γ (IFNγ)+ conventional T cells and locally expanded IL-17A+ innate-like T cells. Single-cell RNA transcriptomics reveals that rhIL-7-hyFc upregulates antiviral genes in pulmonary T cells and induces clonal expansion of type 17 innate-like T cells. rhIL-7-hyFc-mediated disease prevention is dependent on IL-17A in both IAV- and SARS-CoV-2-infected mice. Collectively, we suggest that rhIL-7-hyFc can be used as a broadly active therapeutic for future respiratory virus pandemic.

논문정보

형식Research article
게재일2024년 01월 (BRIC 등록일 2024-01-22)
연구진국내 연구진
분야 생명과학 > 면역학

댓글 작성 로그인

CV 열람하기

연락처 보기